Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
4(44%)
Results Posted
167%(5 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_2
5
56%
Ph early_phase_1
1
11%
Ph not_applicable
3
33%

Phase Distribution

1

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 2Efficacy & side effects
5(55.6%)
N/ANon-phased studies
3(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

4

trials recruiting

Total Trials

9

all time

Status Distribution
Active(4)
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2
Recruiting2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
4
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (11.1%)
Phase 25 (55.6%)
N/A3 (33.3%)

Trials by Status

terminated222%
recruiting222%
completed333%
active_not_recruiting222%

Recent Activity

4 active trials
Showing 5 of 9
active_not_recruitingphase_2

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

NCT02398773
recruitingphase_2

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT07112053
active_not_recruitingphase_2

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

NCT04692103
recruitingphase_2

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

NCT06260033
terminatednot_applicable

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

NCT02149173
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02398773Phase 2

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Active Not Recruiting
NCT07112053Phase 2

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Recruiting
NCT04692103Phase 2

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Active Not Recruiting
NCT06260033Phase 2

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

Recruiting
NCT02149173Not Applicable

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Terminated
NCT00602043Phase 2

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Completed
NCT01720602Not Applicable

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

Completed
NCT02374931Early Phase 1

18F-FES PET/CT in Imaging Patients With Desmoid Tumors

Terminated
NCT01153672Not Applicable

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9